CXCR4
C-X-C chemokine receptor type 4
As of the edition of 20 October 2026, CXCR4 (C-X-C chemokine receptor type 4, UniProt P61073) has 11 drugs tested at it and 14 companies on the list, 6 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P61073
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 33
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Inherited and neonatal; Digestive system; Nutrition and metabolism; Urinary and reproductive
- Registered trials of its drugs
- 215
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 4 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Plerixafor | Marketed | Phase 4 | none listed |
| Motixafortide | Marketed | Phase 4 | none listed |
| Mavorixafor | Marketed | Phase 3 | Ends 2031 |
| Balixafortide | Stopped | Phase 3 | none listed |
| Ulocuplumab | Stopped | Phase 2 | none listed |
| Burixafor | Went quiet | Phase 2 | none listed |
| LY2510924 | Went quiet | Phase 2 | none listed |
| GMI-1359 | Stopped | Phase 1 | none listed |
| MSX-122 | Stopped | Phase 1 | none listed |
| PTX-9908 | Active | Phase 2 | none listed |
| Motixafortide acetate | Marketed | No phase stated | Ends 2030 |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 3 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Sanofi | Route B |
| Bristol Myers Squibb | Route A |
| Eli Lilly | Route A |
The other 11 companies at CXCR4
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at CXCR4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.